

Chapter 9

BIBLIOGRAPHY

1. Hiramatsu, K., Hanaki, H., Ino, T., Yabuta, K., Oguri, T., & Tenover, F. C. (1997). Methicillin-resistant *Staphylococcus aureus* clinical strain with reduced vancomycin susceptibility. *The Journal of antimicrobial chemotherapy*, *40*(1), 135-136.
2. Howden, B. P., Davies, J. K., Johnson, P. D., Stinear, T. P., & Grayson, M. L. (2010). Reduced vancomycin susceptibility in *Staphylococcus aureus*, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. *Clinical microbiology reviews*, *23*(1), 99-139.
3. Garnier, F., Chainier, D., Walsh, T., Karlsson, A., Bolmström, A., Grelaud, C., ... & Ploy, M. C. (2005). A 1 year surveillance study of glycopeptide-intermediate *Staphylococcus aureus* strains in a French hospital. *Journal of Antimicrobial Chemotherapy*, *57*(1), 146-149.
4. Di Gregorio, S., Perazzi, B., Ordonez, A. M., De Gregorio, S., Foccoli, M., Lasala, M. B., ... & Mollerach, M. (2015). Clinical, microbiological, and genetic characteristics of heteroresistant vancomycin-intermediate *Staphylococcus aureus* bacteremia in a teaching hospital. *Microbial Drug Resistance*, *21*(1), 25-34.
5. Perazzi, B., Bello, N., Mollerach, M., Vay, C., Lasala, M. B., & Famiglietti, A. (2011). Endocarditis caused by methicillin-susceptible *Staphylococcus aureus* with reduced susceptibility to vancomycin: a case report. *Journal of medical case reports*, *5*(1), 292.
6. Hiramatsu, K. (2001). Vancomycin-resistant *Staphylococcus aureus*: a new model of antibiotic resistance. *The Lancet infectious diseases*, *1*(3), 147-155.
7. Georgios, M. (2012). Heteroresistance. In *Infection Control-Updates*. InTech.

8. Plata, K., Rosato, A. E., & Wegrzyn, G. (2009). Staphylococcus aureus as an infectious agent: overview of biochemistry and molecular genetics of its pathogenicity. *Acta Biochimica Polonica*, 56(4), 597.
9. Paul Tulkens, Françoise Van Bambeke, Paul Carve. (2008) . Intracellular Fate of Staphylococcus Aureus in Human Phagocytic and Non Phagocytic Cells and Role of Virulence Factors: 1-186
10. Szabó, J. (2009). hVISA/VISA: diagnostic and therapeutic problems. *Expert review of anti-infective therapy*, 7(1), 1-3.
11. Deresinski, S. (2009). Vancomycin heteroresistance and methicillin-resistant Staphylococcus aureus. *The Journal of infectious diseases*, 199(5), 605-609.
12. Butterfield, J. M., Tsuji, B. T., Brown, J., Ashley, E. D., Hardy, D., Brown, K., ... & Lodise, T. P. (2011). Predictors of agr dysfunction in methicillin-resistant Staphylococcus aureus (MRSA) isolates among patients with MRSA bloodstream infections. *Antimicrobial agents and chemotherapy*, 55(12), 5433-5437.
13. Tsompanidou, E., Sibbald, M. J., Chlebowicz, M. A., Dreisbach, A., Back, J. W., van Dijl, J. M., ... & Denham, E. L. (2011). Requirement of the agr locus for colony spreading of Staphylococcus aureus. *Journal of bacteriology*, 193(5), 1267-1272.
14. Türkyilmaz, S., & Kaya, O. (2006). Determination of some virulence factors in Staphylococcus spp. isolated from various clinical samples. *Turkish Journal of Veterinary and Animal Sciences*, 30(1), 127-132.
15. Winn, W. C. (2006). *Koneman's color atlas and textbook of diagnostic microbiology*. Lippincott williams & wilkins.
16. Narayanan, A. R & Jayaram Panicker CK, Text Book of Medical Microbiology.

17. Arslan, S., & Ozkardes, F. (2007). Slime production and antibiotic susceptibility in staphylococci isolated from clinical samples. *Memórias do Instituto Oswaldo Cruz*, 102(1), 29-33.
18. Kirmusaoglu, S. (2016). Staphylococcal biofilms: pathogenicity, mechanism and regulation of biofilm formation by quorum-sensing system and antibiotic resistance mechanisms of biofilm-embedded microorganisms. In *Microbial Biofilms-Importance and Applications*. InTech.
19. Olivier, A. C., Lemaire, S., Van Bambeke, F., Tulkens, P. M., & Oldfield, E. (2009). Role of rsbU and staphyloxanthin in phagocytosis and intracellular growth of *Staphylococcus aureus* in human macrophages and endothelial cells. *The Journal of infectious diseases*, 200(9), 1367-1370.
20. Arvidson, S., & Tegmark, K. (2001). Regulation of virulence determinants in *Staphylococcus aureus*. *International journal of medical microbiology*, 291(2), 159-170.
21. Auwaerter, P. G. (2006). Cellulitis, Skin Abscesses, and Community-Acquired Methicillin-Resistant *Staphylococcus Aureus*. *ADVANCED STUDIES IN MEDICINE*, 6(2), 62.
22. Bartlett, J. G. (2011). *Johns Hopkins ABX Guide 2012*. Jones & Bartlett Publishers.
23. Rayner, C., & Munckhof, W. J. (2005). Antibiotics currently used in the treatment of infections caused by *Staphylococcus aureus*. *Internal medicine journal*, 35(s2).
24. Lowy, F. D. (2003). Antimicrobial resistance: the example of *Staphylococcus aureus*. *Journal of Clinical Investigation*, 111(9), 1265.
25. Ferreira, A. M., Martins, K. B., Silva, V. R. D., Mondelli, A. L., & Cunha, M. D. L. R. D. (2017). Correlation of phenotypic tests with the presence of

- the blaZ gene for detection of beta-lactamase. *brazilian journal of microbiology*, 48(1), 159-166.
26. Katayama, Y., Ito, T., & Hiramatsu, K. (2000). A new class of genetic element, staphylococcus cassette chromosome mec, encodes methicillin resistance in *Staphylococcus aureus*. *Antimicrobial agents and chemotherapy*, 44(6), 1549-1555.
 27. Stapleton, P. D., & Taylor, P. W. (2002). Methicillin resistance in *Staphylococcus aureus*: mechanisms and modulation. *Science progress*, 85(1), 57-72.
 28. Gould, I. M., David, M. Z., Esposito, S., Garau, J., Lina, G., Mazzei, T., & Peters, G. (2012). New insights into methicillin-resistant *Staphylococcus aureus* (MRSA) pathogenesis, treatment and resistance. *International journal of antimicrobial agents*, 39(2), 96-104.
 29. Swenson, J. M., Williams, P. P., Killgore, G., O'Hara, C. M., & Tenover, F. C. (2001). Performance of Eight Methods, Including Two New Rapid Methods, for Detection of Oxacillin Resistance in a Challenge Set of *Staphylococcus aureus* Organisms. *Journal of Clinical Microbiology*, 39(10), 3785-3788.
 30. Datta, P., Gulati, N., Singla, N., Vasdeva, H. R., Bala, K., Chander, J., & Gupta, V. (2011). Evaluation of various methods for the detection of methicillin-resistant *Staphylococcus aureus* strains and susceptibility patterns. *Journal of medical microbiology*, 60(11), 1613-1616.
 31. Diederer, B., van Duijn, I., van Belkum, A., Willemse, P., van Keulen, P., & Kluytmans, J. (2005). Performance of CHROMagar MRSA medium for detection of methicillin-resistant *Staphylococcus aureus*. *Journal of clinical microbiology*, 43(4), 1925-1927.
 32. Bouchami, O., Achour, W., & Ben Hassen, A. (2007). Prevalence and mechanisms of macrolide resistance among *Staphylococcus epidermidis*

- isolates from neutropenic patients in Tunisia. *Clinical microbiology and infection*, 13(1), 103-106.
33. Prabhu, K., Rao, S., & Rao, V. (2011). Inducible clindamycin resistance in *Staphylococcus aureus* isolated from clinical samples. *Journal of laboratory physicians*, 3(1), 25.
 34. Hiramatsu, K., Cui, L., Kuroda, M., & Ito, T. (2001). The emergence and evolution of methicillin-resistant *Staphylococcus aureus*. *Trends in microbiology*, 9(10), 486-493.
 35. Hu, J., Ma, X. X., Tian, Y., Pang, L., Cui, L. Z., & Shang, H. (2013). Reduced vancomycin susceptibility found in methicillin-resistant and methicillin-sensitive *Staphylococcus aureus* clinical isolates in Northeast China. *PloS one*, 8(9), e73300.
 36. Groicher, K. H., Firek, B. A., Fujimoto, D. F., & Bayles, K. W. (2000). The *Staphylococcus aureus* *lrgAB* operon modulates murein hydrolase activity and penicillin tolerance. *Journal of bacteriology*, 182(7), 1794-1801.
 37. Devi, Y., Punithavathy, P. M., Thomas, S., & Veeraraghavan, B. (2015). Challenges in the Laboratory Diagnosis and Clinical Management of Heteroresistant Vancomycin *Staphylococcus aureus* (hVISA). *Clinical Microbiology: Open Access*.
 38. Bailey, W. R., & Scott, E. G. (1974). *Diagnostic microbiology: a textbook for the isolation and identification of pathogenic microorganisms*. Mosby Incorporated.
 39. Clinical Laboratory Standard Institute Guidelines 2014
 40. Wootton, M., Howe, R. A., Hillman, R., Walsh, T. R., Bennett, P. M., & MacGowan, A. P. (2001). A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in *Staphylococcus aureus* in a UK hospital. *Journal of Antimicrobial Chemotherapy*, 47(4), 399-403.

41. Sakoulas, G., Eliopoulos, G. M., Fowler, V. G., Moellering, R. C., Novick, R. P., Lucindo, N., ... & Bayer, A. S. (2005). Reduced susceptibility of *Staphylococcus aureus* to vancomycin and platelet microbicidal protein correlates with defective autolysis and loss of accessory gene regulator (*agr*) function. *Antimicrobial Agents and Chemotherapy*, 49(7), 2687-2692.
42. Auttawit Sirichoat, Sujintana Wongthong, Rattawan Kanyota, Ratre Tavichakorntrakool, Aroonwadee Chanawong, Jariya Umka Welbat, and Aroonlug Lulitanond. (2016) . Phenotypic Characteristics of Vancomycin-Non-Susceptible *Staphylococcus aureus* Jundishapur Journal of Microbiogyl. 9(1): 260- 69
43. Selvabai, A. P., Banu, A. S., Jeya, M., & Shanmugam, P. (2017). Characterization of Methicillin Resistant *Staphylococcus aureus* based on its virulence factors and antimicrobial susceptibility profile. *Indian Journal of Microbiology Research*, 4(1), 74-78.
44. Kwasny, Steven M., and Timothy J. Opperman. (2010). Static Biofilm Cultures of Gram-Positive Pathogens Grown in a Microtiter Format Used for Anti-Biofilm Drug Discovery. *Current protocols in pharmacology* 13A-8
45. Stepanović, S., Vuković, D., Dakić, I., Savić, B., & Švabić-Vlahović, M. (2000). A modified microtiter-plate test for quantification of staphylococcal biofilm formation. *Journal of microbiological methods*, 40(2), 175-179.
46. Bello, C. S. S., & Qahtani, A. (2005). Pitfalls in the routine diagnosis of *Staphylococcus aureus*. *African Journal of Biotechnology*, 4(1), 83.
47. Wiseman, G. M. (1975). The hemolysins of *Staphylococcus aureus*. *Bacteriological reviews*, 39(4), 317.
48. Shahin Najar Peerayeh, Amir Azimian, Qorban Behzadian Nejad, Mohtar Kashi. (2009) . Prevalence of *agr* Specificity Groups Among *Staphylococcus aureus* Isolates From University Hospitals in Tehran. *LabMedicine*. 40 (1):27-29.

49. Melake, N. A., Zakaria, A. S., Ibrahim, N. H., Salama, M. A., & Mahmoud, A. Z. (2014). Prevalence of agr specificity groups among in vitro biofilm forming methicillin resistant *Staphylococcus aureus* strains isolated from nasal carriers. *International Journal of Microbiological Research*, 5(2), 76-84.
50. Indian Network for Surveillance of Antimicrobial Resistance (INSAR) group. Methicillin resistant *Staphylococcus aureus* (MRSA) in India: Prevalence & susceptibility pattern. *The Indian journal of medical research*. 2013;137(2):363.
51. Chaudhari, C. N., Tandel, K., Grover, N., Sen, S., Bhatt, P., Sahni, A. K., & Praharaj, A. K. (2015). Heterogeneous vancomycin-intermediate among methicillin resistant *Staphylococcus aureus*. *medical journal armed forces india*, 71(1), 15-18.
52. Song, J. H., Hsueh, P. R., Chung, D. R., Ko, K. S., Kang, C. I., Peck, K. R., ... & Jung, S. I. (2011). Spread of methicillin-resistant *Staphylococcus aureus* between the community and the hospitals in Asian countries: an ANSORP study. *Journal of antimicrobial chemotherapy*, 66(5), 1061-1069.
53. Wang, G., Hindler, J. F., Ward, K. W., & Bruckner, D. A. (2006). Increased vancomycin MICs for *Staphylococcus aureus* clinical isolates from a university hospital during a 5-year period. *Journal of clinical microbiology*, 44(11), 3883-3886.
54. Monica, C. (2002). *Microbiology Tests Part 2*.
55. de Oliveira Silveira, A. C., Sambrano, G. E., da Silva Paim, T. G., Caierão, J., de Cordova, C. M. M., & d'Azevedo, P. A. (2014). Is prediffusion test an alternative to improve accuracy in screening hVISA strains and to detect susceptibility to glycopeptides/lipopeptides?. *Diagnostic microbiology and infectious disease*, 79(4), 401-404.
56. Kateete, D. P., Kimani, C. N., Katabazi, F. A., Okeng, A., Okee, M. S., Nanteza, A., ... & Najjuka, F. C. (2010). Identification of *Staphylococcus*

- aureus: DNase and Mannitol salt agar improve the efficiency of the tube coagulase test. *Annals of clinical microbiology and antimicrobials*, 9(1), 23.
57. Desouky, S. E., El-Gamal, M. S., Mohammed, A. F., & Abu-Elghait, M. A. (2014). Determination of some virulence factors in *Staphylococcus* spp. isolated from clinical samples of different Egyptian patients. *World Applied Sciences Journal*, 32(4), 731-740.
58. Rupp, M. E., Ulphani, J. S., Fey, P. D., & Mack, D. (1999). Characterization of *Staphylococcus epidermidis* Polysaccharide Intercellular Adhesin/Hemagglutinin in the Pathogenesis of Intravascular Catheter-Associated Infection in a Rat Model. *Infection and Immunity*, 67(5), 2656-2659.
59. Rupp, M. E., Han, J., & Gattermann, S. (1995). Hemagglutination by *Staphylococcus aureus* strains responsible for human bacteremia or bovine mastitis. *Medical microbiology and immunology*, 184(1), 33-36.
60. Hammadi, K. M., & Yousif, A. A. (2014). Detection of slime material in *Staphylococcus aureus* bacteria from ovine mastitis by transmission electron microscope and Congo red agar method. *Int. J. Curr. Microbiol. App. Sci*, 3(4), 304-309.
61. Podbielska, A., Galkowska, H., Stelmach, E., Mlynarczyk, G., & Olszewski, W. L. (2010). Slime production by *Staphylococcus aureus* and *Staphylococcus epidermidis* strains isolated from patients with diabetic foot ulcers. *Archivum immunologiae et therapiae experimentalis*, 58(4), 321-324.
62. Otto, M. (2008). Staphylococcal biofilms. *Bacterial biofilms*, 207-228.
63. Rezaei, M., Moniri, R., Mousavi, S. G. A., & Shiade, M. J. (2013). Prevalence of biofilm formation among methicillin resistance *Staphylococcus aureus* isolated from nasal carriers. *Jundishapur Journal of Microbiology*, 6(6).

64. Moghadam, S. O., Pourmand, M. R., & Aminharati, F. (2014). Biofilm formation and antimicrobial resistance in methicillin-resistant *Staphylococcus aureus* isolated from burn patients, Iran. *The Journal of Infection in Developing Countries*, 8(12), 1511-1517.
65. Howden, B. P., Johnson, P. D., Ward, P. B., Stinear, T. P., & Davies, J. K. (2006). Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant *Staphylococcus aureus* bacteremia. *Antimicrobial Agents and Chemotherapy*, 50(9), 3039-3047.
66. Ali Maki Hamed Al-Dahbi. (2013). Comparative study between Methicillin Resistant *Staphylococcus aureus* (MRSA) *agr* + isolates and MRSA *agr* – isolates
67. Singh, A., Prasad, K. N., Rahman, M., Rai, R. P., Singh, S. K., & Srivastava, J. K. (2017). High frequency of SCCmec type V and *agr* type I among heterogeneous vancomycin-intermediate *Staphylococcus aureus* (hVISA) in north India. *Journal of global antimicrobial resistance*, 8, 110-114.
68. Moise-Broder, P. A., Sakoulas, G., Eliopoulos, G. M., Schentag, J. J., Forrest, A., & Moellering Jr, R. C. (2004). Accessory gene regulator group II polymorphism in methicillin-resistant *Staphylococcus aureus* is predictive of failure of vancomycin therapy. *Clinical infectious diseases*, 38(12), 1700-1705.
69. Chong, Y. P., Kim, E. S., Park, S. J., Park, K. H., Kim, T., Kim, M. N., ... & Jeong, J. Y. (2013). Accessory gene regulator (*agr*) dysfunction in *Staphylococcus aureus* bloodstream isolates from South Korean patients. *Antimicrobial agents and chemotherapy*, 57(3), 1509-1512.
70. Chaturvedi, P., Singh, A. K., Singh, A. K., Shukla, S., & Agarwal, L. (2014). Prevalence of mupirocin resistant *Staphylococcus aureus* isolates among patients admitted to a tertiary care hospital. *North American journal of medical sciences*, 6(8), 403.